Evidence map›Paper›PMID 35292515›Full record

ArticleJournal for immunotherapy of cancer2022

IL-1R8 silencing improves the anti-tumor function of freshly isolated human NK cells.

Nadine Landolina, Francesca Romana Mariotti, Tiziano Ingegnere, Claudia Alicata, Biancamaria Ricci, Andrea Pelosi, Irene Veneziani, Bruno Giuseppe Azzarone, Cecilia Garlanda, Alberto Mantovani and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Interleukin-18 armours antitumour immune effectors.Nature reviews. Immunology · 2026
    Review
  3. Review
  4. Review
  5. IL-1 family cytokines in inflammation and immunity.Cellular & molecular immunology · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Nadine Landolina *Immunology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.ORCID 0000-0002-6110-6146
Francesca Romana Mariotti *Immunology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.ORCID 0000-0002-3421-6470
Tiziano Ingegnere *Immunology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.ORCID 0000-0001-9179-0447
Claudia AlicataImmunology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.ORCID 0000-0003-2053-626X
Biancamaria RicciImmunology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Andrea PelosiImmunology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.ORCID 0000-0003-2308-9215
Irene VenezianiImmunology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.ORCID 0000-0002-1243-3757
Bruno Giuseppe AzzaroneImmunology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.ORCID 0000-0002-5962-3849
Cecilia GarlandaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy.
Alberto MantovaniDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy.ORCID 0000-0001-5578-236X
Lorenzo MorettaImmunology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy lorenzo.moretta@opbg.net.ORCID 0000-0003-4658-1747
Enrico MaggiImmunology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.ORCID 0000-0002-1824-3583
Bambino Gesù Children's Hospital · ITHumanitas University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inhibitory receptor interleukin-1 receptor 8 (IL-1R8) has been recently recognized to be expressed also by human natural killer (NK) cells. This study was aimed to design and optimize IL-1R8 silencing conditions in human NK cells to precisely establish the activity of such receptor in these cells. Electroporation of freshly isolated or IL-2-cultured NK cells with small interfering RNA (siRNA), resulted in a marked, even though variable, IL-1R8-silencing. Although the expression profile revealed downregulation of most genes involved in several intracellular pathways, some genes related to proliferation, expression of some chemokine receptors, antibody-dependent cell cytotoxicity and cytotoxic activity were upregulated in IL-1R8-silenced NK cells. Furthermore, upon IL-15 activation, the majority of genes involved in NK cell function were upregulated in IL-1R8-siRNA-compared with control-siRNA-transfected NK cells. More importantly, in agreement with these findings, the reduction of IL-1R8 gene expression levels resulted in enhanced expression of NK cell activation markers, production of cytokines and chemokines, and cytotoxic activity against several NK cell targets with different susceptibility to NK-mediated lysis. Similar results were obtained following stimulation with IL-18. All together these data, deeply impacting on the main effector functions of human NK cells, can lead to a better understanding of IL-1R8-mediated regulation on these cells and to the design of new strategies for improving NK cell-mediated anti-tumor responses.

Indexed as

Antineoplastic AgentsKiller Cells, NaturalAntibody-Dependent Cell CytotoxicityCytokinesHumansLymphocyte ActivationReceptors, Interleukin-1 Type IAntineoplastic AgentsCytokinesReceptors, Interleukin-1 Type Iimmunomodulationimmunotherapynatural killer cells

Identifiers

PMID35292515
PMCPMC8928329
OpenAlexW4220692630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.